A PHASE 3, OPEN-LABEL, MULTICENTER STUDY OF THE SAFETY/TOLERABILITY AND EFFICACY OF BRINCIDOFOVIR (CMX001) FOR THE PREVENTION OF ADENOVIRUS (ADV) DISEASE IN SUBJECTS WITH ASYMPTOMATIC ADV INFECTION AT RISK OF PROGRESSION AND FOR THE TREATMENT OF SUBJECTS WITH LOCALIZED OR DISSEMINATED ADV DISEASE.

Registry ID

CMX001-304

Source registry

HEALTH_CANADA

Status

Pending

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

CHIMERIX INC

Last update

2014-10-30

Conditions

• ADENOVIRUS

Related clinical trials

• A PHASE 3, MULTICENTER, PROSPECTIVE, RANDOMIZED, OPEN-LABEL EFFICACY AND SAFETY STUDY OF INTRAVENOUS BRINCIDOFOVIR VERSUS INTRAVENOUS CIDOFOVIR FOR TREATMENT OF ADENOVIRUS INFECTION IN PEDIATRIC AND ADULT SUBJECTS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (ALLO-HCT)
• PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, WITH CROSS-OVER, OF POSOLEUCEL (ALVR105) FOR THE TREATMENT OF ADENOVIRUS INFECTION IN PEDIATRIC AND ADULT PARTICIPANTS RECEIVING STANDARD OF CARE FOLLOWING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION

View on source registry